# US 11,441,148 B2 · Modulators and modulation of the receptor for advanced glycation end-products RNA > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 11,441,148 B2 - Document ID: US11441148B2 - Status: Granted - Kind: B2 - Application number: 17/411,932 - Filed: 2021-08-25 - Published: 2021-12-16 - Granted: 2022-09-13 - Earliest claimed: 2019-05-14 - Assignees: Monash University; Murdoch University - Applicants: Monash University; Murdoch University - Inventors: Stephen Wilton; Merlin Christopher Thomas; Carlos Rosado; Raelene Jane Pickering - Web page: https://patentgrep.com/patent/US11441148B2 ## CPC - A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 - C12N 15/1138: {against receptors or cell surface proteins} - C12N 2310/11: Antisense - C12N 2310/315: Phosphorothioates - C12N 2310/321: 2'-O-R Modification - C12N 2310/3233: Morpholino-type ring - C12N 2310/3513: Protein; Peptide - C12N 2320/30: Special therapeutic applications - C12N 2320/33: Alteration of splicing - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS - C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00) ## Abstract An isolated or purified AON for modifying pre-mRNA splicing in the Receptor for Advanced Glycation End-products (RAGE) to modulate splicing of the RAGE gene transcript or part thereof is provided. ## Claims ### Claim 1 A method for manipulating splicing in a Receptor for Advanced Glycation End-products (RAGE) pre-mRNA resulting in the skipping of exon 10, the method comprising: contacting a cell with one or more antisense oligonucleotides having a nucleotide sequence at least 85% complementary to an identified target region of exon 10 of RAGE pre-mRNA over the entirety of the antisense oligonucleotide, wherein, in the identified target region, the 5′-most nucleotide is nucleotide position 88 or 114 of exon 10 or is between nucleotide positions 88 to 114 of exon 10, and wherein the identified target region enhances alternative splicing to exclude exon 10 and to generate a soluble form of RAGE; and further wherein the one or more antisense oligonucleotides binds to the RAGE pre-mRNA within the identified target region; wherein the one or more antisense oligonucleotides is 8 to 25 nucleotides in length; wherein the one or more antisense oligonucleotides comprises at least one modified nucleotide; and manipulating splicing in the RAGE pre-mRNA resulting in the skipping of exon 10 and reducing the expression of RAGE mRNA containing exon 10 by the binding of the one or more antisense oligonucleotides to the target region of exon 10 in the RAGE pre-mRNA. ### Claim 2 (depends on 1) The method according to claim 1, wherein the 5′-most nucleotide of the target region is between nucleotide positions 90 to 114 of exon 10 of RAGE pre-mRNA. ### Claim 3 (depends on 1) The method according to claim 1, wherein the 5′-most nucleotide of the target region is between nucleotide positions 88 to 107 of exon 10 of RAGE pre-mRNA. ### Claim 4 (depends on 1) The method according to claim 1, wherein the 5′-most nucleotide of the target region is between nucleotide positions 90 to 102 of exon 10 of RAGE pre-mRNA. ### Claim 5 (depends on 1) The method according to claim 1, wherein the target region is between nucleotide positions 90 to 114 of exon 10 of RAGE pre-mRNA. ### Claim 6 (depends on 1) The method according to claim 1, wherein the target region is between nucleotide positions 88 to 107 of exon 10 of RAGE pre-mRNA. ### Claim 7 (depends on 1) The method according to claim 1, wherein the target region is between nucleotide positions 90 to 102 of exon 10 of RAGE pre-mRNA. ### Claim 8 (depends on 1) The method according to claim 1, wherein antisense oligonucleotide has a nucleotide sequence at least 90% complementary to the target region of exon 10 of RAGE pre-mRNA. ### Claim 9 (depends on 1) The method according to claim 1, wherein antisense oligonucleotide has a nucleotide sequence at least 95% complementary to the target region of exon 10 of RAGE pre-mRNA. ### Claim 10 (depends on 1) The method according to claim 1, wherein antisense oligonucleotide has a nucleotide sequence that is 100% complementary to the target region of exon 10 of RAGE pre-mRNA. ### Claim 11 (depends on 1) The method according to claim 1, wherein the antisense oligonucleotide is 8 to 15 nucleotides in length. ### Claim 12 (depends on 11) The method according to claim 11, wherein the antisense oligonucleotide is 9 to 14 nucleotides in length. ### Claim 13 (depends on 12) The method according to claim 12, wherein the antisense oligonucleotide is 13 nucleotides in length. ### Claim 14 (depends on 13) The method according to claim 13, wherein the target region is between nucleotide positions 90 to 114 of exon 10 of RAGE pre-mRNA. ### Claim 15 (depends on 13) The method according to claim 13, wherein the target region is between nucleotide positions 88 to 107 of exon 10 of RAGE pre-mRNA. ### Claim 16 (depends on 13) The method according to claim 13, wherein the target region is between nucleotide positions 90 to 102 of exon 10 of RAGE pre-mRNA. ### Claim 17 (depends on 1) The method according to claim 1, wherein the modified nucleotide comprises any one or more of a morpholino group, a modified linkage, or a modified sugar moiety. ### Claim 18 (depends on 17) The method according to claim 17, wherein the modified sugar moiety comprises methylation at a 2′ hydroxyribose position. ### Claim 19 (depends on 17) The method according to claim 17, wherein the modified linkage is a phosphorothioate linkage. ### Claim 20 (depends on 1) The method according to claim 1, wherein the antisense oligonucleotide is a phosphorodiamidate morpholino oligomer (PMO). ### Claim 21 (depends on 1) The method according to claim 1, wherein the antisense oligonucleotide is further modified by: (i) chemical conjugation to a moiety; and/or (ii) tagging with a cell penetrating peptide. ### Claim 22 (depends on 1) The method according to claim 1, wherein, if a uracil is present in the antisense oligonucleotide, the uracil (U) of the antisense oligonucleotide is replaced by a thymine (T). ### Claim 23 A method of treating a disease associated with RAGE expression, the method comprising: administering to a patient an effective amount of an antisense oligonucleotide having a nucleotide sequence at least 85% complementary to an identified target region of exon 10 of RAGE pre-mRNA over the entirety of the antisense oligonucleotide, wherein, in the identified target region, the 5′-most nucleotide is nucleotide position 88 or 114 of exon 10 or is between nucleotide positions 88 to 114 of exon 10, and wherein the identified target region enhances alternative splicing to exclude exon 10 and to generate a soluble form of RAGE; and further wherein the antisense oligonucleotide binds to the RAGE pre-mRNA within the identified target region; wherein the antisense oligonucleotide is 8 to 25 nucleotides in length; and wherein the antisense oligonucleotide comprises at least one modified nucleotide; thereby treating the disease. ### Claim 24 (depends on 23) The method of claim 23, wherein the disease associated with RAGE expression is selected from the group consisting of neurodegenerative disease, cancer, lung disorders, and inflammatory disease. ### Claim 25 (depends on 23) The method of claim 23, wherein the antisense oligonucleotide is 20 to 25 nucleotides in length. ### Claim 26 (depends on 1) The method of claim 1, wherein the target region of exon 10 of the RAGE pre-mRNA contains at least one guanine (G)-rich cis element and wherein the binding of the one or more antisense oligonucleotides within exon 10 flanks the G-rich cis element. ### Claim 27 (depends on 26) The method of claim 26, wherein the at least one guanine (G)-rich cis element is bound by a heterogeneous nuclear ribonucleoprotein H (hnRNP).